Moving Naloxone Over the Counter Is Necessary but Not Sufficient

Editorial Material Medicine, General & Internal

Assessing-and Extending-California's Insulin Manufacturing Initiative

Jacob S. Sherkow et al.

Summary: This Viewpoint examines California's CalRx initiative, which aims to produce biosimilar insulin, discusses the challenges it faces, and suggests ways it could serve as a model for state-managed drug development, reduce drug prices, and offer additional benefits.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Add to Collection

Editorial Material Medicine, General & Internal

When States Step Up: California and the Case for State-Led Insulin Manufacturing

Mariana P. Socal et al.

ANNALS OF INTERNAL MEDICINE (2022)

Add to Collection

Article Substance Abuse

Associations Between Copays, Coverage Limits for Naloxone, and Prescribing in Medicaid

John C. Messinger et al.

Summary: This study aimed to describe the dispensing of naloxone in Medicaid fee-for-service (FFS) and examine the relationships between copays and coverage limits for naloxone and its dispensing rates. The findings showed substantial variation in naloxone dispensing rates across the US for Medicaid patients, but no meaningful relationship was found between plan design and dispensing. Further evaluation is needed to determine if drug benefit designs in Medicaid influence naloxone use and ensure access to this life-saving medication.

SUBSTANCE ABUSE-RESEARCH AND TREATMENT (2022)

Add to Collection

Article Health Care Sciences & Services

Trends in Out-of-Pocket Costs for Naloxone by Drug Brand and Payer in the US, 2010-2018

Evan D. Peet et al.

Summary: The study analyzed US naloxone claims data from 2010 to 2018 and found that out-of-pocket costs for naloxone have increased significantly since 2016, particularly for uninsured patients and the Evzio brand. This highlights that the out-of-pocket cost of naloxone has become a significant barrier to access for uninsured patients.

JAMA HEALTH FORUM (2022)

Add to Collection

Review Psychiatry

Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence A Systematic Review and Meta-analysis

Thomas Santo Jr et al.

Summary: This systematic review and meta-analysis found that OAT was associated with lower rates of mortality. However, access to OAT remains limited, and insurance coverage remains low. Work to improve access globally may have important population-level benefits.

JAMA PSYCHIATRY (2021)

Add to Collection

Article Public, Environmental & Occupational Health